Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial | Zendy

Fergus Hamilton | Zendy; Todd C. Lee | Zendy; David Arnold | Zendy; Richard Lilford | Zendy; Karla Hemming | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial

Author(s) -

Fergus Hamilton,

Todd C. Lee,

David Arnold,

Richard Lilford,

Karla Hemming

Publication year - 2021

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2021.06.034

Subject(s) - convalescent plasma , covid-19 , bayesian probability , randomized controlled trial , medicine , statistics , mathematics , disease , infectious disease (medical specialty)

Randomized trials are generally performed from a frequentist perspective, which can conflate absence of evidence with evidence of absence. The RECOVERY trial evaluated convalescent plasma for patients hospitalized with coronavirus disease 2019 (COVID-19) and concluded that there was no evidence of an effect. Re-analysis from a Bayesian perspective is warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research